180 related articles for article (PubMed ID: 29142970)
1. Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Hayek SS; Ko YA; Awad M; Ahmed H; Gray B; Hosny KM; Aida H; Tracy MJ; Wei C; Sever S; Reiser J; Quyyumi AA
Kidney Int Rep; 2017 May; 2(3):425-432. PubMed ID: 29142970
[TBL] [Abstract][Full Text] [Related]
2. Soluble Urokinase Receptor and Chronic Kidney Disease.
Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
[TBL] [Abstract][Full Text] [Related]
3. Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.
Schaefer F; Trachtman H; Wühl E; Kirchner M; Hayek SS; Anarat A; Duzova A; Mir S; Paripovic D; Yilmaz A; Lugani F; Arbeiter K; Litwin M; Oh J; Matteucci MC; Gellermann J; Wygoda S; Jankauskiene A; Klaus G; Dusek J; Testa S; Zurowska A; Caldas Afonso A; Tracy M; Wei C; Sever S; Smoyer W; Reiser J;
JAMA Pediatr; 2017 Nov; 171(11):e172914. PubMed ID: 28873129
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Hayek SS; Landsittel DP; Wei C; Zeier M; Yu ASL; Torres VE; Roth S; Pao CS; Reiser J
J Am Soc Nephrol; 2019 Jul; 30(7):1305-1313. PubMed ID: 31171572
[TBL] [Abstract][Full Text] [Related]
5. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
[TBL] [Abstract][Full Text] [Related]
6. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease.
Iversen E; Kallemose T; Hornum M; Bengaard AK; Nehlin JO; Rasmussen LJH; Sandholdt H; Tavenier J; Feldt-Rasmussen B; Andersen O; Eugen-Olsen J; Houlind MB
Clin Kidney J; 2022 Aug; 15(8):1534-1541. PubMed ID: 35892012
[TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
[TBL] [Abstract][Full Text] [Related]
9. Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD.
Sommerer C; Müller-Krebs S; Nadal J; Schultheiss UT; Friedrich N; Nauck M; Schmid M; Nußhag C; Reiser J; Eckardt KU; Zeier M; Hayek SS;
Kidney Int Rep; 2023 Nov; 8(11):2265-2275. PubMed ID: 38025216
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
[TBL] [Abstract][Full Text] [Related]
11. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Schulz CA; Persson M; Christensson A; Hindy G; Almgren P; Nilsson PM; Melander O; Engström G; Orho-Melander M
Kidney Int Rep; 2017 Mar; 2(2):239-247. PubMed ID: 28367534
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
Höbaus C; Ursli M; Yussef SM; Wrba T; Koppensteiner R; Schernthaner GH
Vasc Med; 2021 Feb; 26(1):11-17. PubMed ID: 33448911
[TBL] [Abstract][Full Text] [Related]
13. Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study.
Gutiérrez OM; Shlipak MG; Katz R; Waikar SS; Greenberg JH; Schrauben SJ; Coca S; Parikh CR; Vasan RS; Feldman HI; Kimmel PL; Cushman M; Bonventre JV; Sarnak MJ; Ix JH
Am J Kidney Dis; 2022 Jun; 79(6):849-857.e1. PubMed ID: 34752914
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease.
Sandesara PB; O'Neal WT; Tahhan AS; Hayek SS; Lee SK; Khambhati J; Topel ML; Hammadah M; Alkhoder A; Ko YA; Gafeer MM; Beshiri A; Murtagh G; Kim JH; Wilson P; Shaw L; Epstein SE; Sperling LS; Quyyumi AA
Am J Cardiol; 2018 Jun; 121(12):1461-1466. PubMed ID: 29628129
[TBL] [Abstract][Full Text] [Related]
15. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
16. Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes.
Le D; Chen J; Shlipak MG; Ix JH; Sarnak MJ; Gutierrez OM; Schelling JR; Bonventre JV; Sabbisetti VS; Schrauben SJ; Coca SG; Kimmel PL; Vasan RS; Grams ME; Parikh C; Coresh J; Rebholz CM;
Kidney Med; 2023 Nov; 5(11):100719. PubMed ID: 37841418
[TBL] [Abstract][Full Text] [Related]
17. Plasma Biomarkers of Tubular Injury and Inflammation Are Associated with CKD Progression in Children.
Greenberg JH; Abraham AG; Xu Y; Schelling JR; Feldman HI; Sabbisetti VS; Gonzalez MC; Coca S; Schrauben SJ; Waikar SS; Ramachandran VS; Shlipak MG; Warady B; Kimmel PL; Bonventre JV; Denburg M; Parikh CR; Furth S;
J Am Soc Nephrol; 2020 May; 31(5):1067-1077. PubMed ID: 32234829
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
[TBL] [Abstract][Full Text] [Related]
19. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.
Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP
Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549
[TBL] [Abstract][Full Text] [Related]
20. Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.
Roehm B; McAdams M; Gordon J; Zhang S; Xu P; Grodin JL; Hedayati SS
J Investig Med; 2024 May; ():10815589241249991. PubMed ID: 38715217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
